Insider · CIK 0001995657
Pamela Wapnick
cfoofficer
Files at MGX (Metagenomi, Inc.). First filing Dec 6, 2024, latest Sep 10, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 3
$0 bought, $7,871 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MGX: Metagenomi, Inc.
MGXOct 9, 2026 · close 1.00
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 37Weak | Metagenomi, Inc. | $2,214 1,911 shares | -1% | - | |
| 37Weak | Metagenomi, Inc. | $2,758 1,576 shares | -2% | +37% from low-59% from high | |
| 22Weak | MGXsell Metagenomi, Inc. | $2,900 1,559 shares | -2% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | MGX Metagenomi, Inc. | SOpen-market sale Common Stock | -1,911 | $1.16 | $2,214 | 206,580 | 32 d ago |
| Jun 6, 2025 | MGX Metagenomi, Inc. | SOpen-market sale Common Stock | -1,576 | $1.75 | $2,758 | 72,108 | Jun 9, 2025 |
| Apr 1, 2025 | MGX Metagenomi, Inc. | AGrant or award Common Stock | +14,000 | $0.00 | $0 | 73,684 | Apr 3, 2025 |
| Apr 1, 2025 | MGX Metagenomi, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +84,000 | $0.00 | $0 | 84,000 | Apr 3, 2025 |
| Dec 5, 2024 | MGX Metagenomi, Inc. | SOpen-market sale Common Stock | -1,559 | $1.86 | $2,900 | 61,492 | Dec 6, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.